RNAimmune
Series A in 2022
RNAimmune, Inc. is a biopharmaceutical company focused on the development of messenger RNA (mRNA) therapeutics and vaccines. Based in Gaithersburg, Maryland, the company utilizes mRNA as a data carrier to instruct the human body to produce proteins that combat a variety of diseases, including cancer, viral infections, and rare diseases. RNAimmune has developed an mRNA design platform and self-amplifying mRNA technology, alongside a proprietary artificial intelligence algorithm known as ALEPVA, which aids in antigen prediction and vaccine design. The company is a spin-off from Sirnaomics, Inc. and holds exclusive rights to the Polypeptide Lipid Nanoparticle (PLNP) technology for mRNA delivery. By integrating these innovative technologies, RNAimmune aims to create a robust platform for mRNA drug discovery and development, addressing significant unmet medical needs in the industry.
SparX Group
Series B in 2021
SparX Group is a biotech firm that develops innovative anticancer biologics through bispecific antibodies and drug conjugates.
Sirnaomics
Series E in 2021
Sirnaomics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing targeted therapeutics for significant human diseases using RNA interference (RNAi) technology. Founded in 2007 and headquartered in Gaithersburg, Maryland, with additional offices in Cambridge, Massachusetts, and facilities in Suzhou and Guangzhou, China, Sirnaomics is dedicated to addressing critical medical needs in oncology, anti-fibrotic therapeutics, and viral infections. The company's product portfolio includes several small interfering RNA (siRNA) therapeutics such as STP705 for scar reduction, STP909 for colon cancer, and STP900 for HPV and cervical cancer, among others. Sirnaomics employs proprietary Polypeptide Nano-Particle (PNP) technology to enhance drug delivery, allowing effective targeting of the tumor microenvironment and various cell types, particularly in the liver. Through its innovative approach, Sirnaomics aims to create impactful treatments for diseases with large market opportunities.
Sirnaomics
Series D in 2020
Sirnaomics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing targeted therapeutics for significant human diseases using RNA interference (RNAi) technology. Founded in 2007 and headquartered in Gaithersburg, Maryland, with additional offices in Cambridge, Massachusetts, and facilities in Suzhou and Guangzhou, China, Sirnaomics is dedicated to addressing critical medical needs in oncology, anti-fibrotic therapeutics, and viral infections. The company's product portfolio includes several small interfering RNA (siRNA) therapeutics such as STP705 for scar reduction, STP909 for colon cancer, and STP900 for HPV and cervical cancer, among others. Sirnaomics employs proprietary Polypeptide Nano-Particle (PNP) technology to enhance drug delivery, allowing effective targeting of the tumor microenvironment and various cell types, particularly in the liver. Through its innovative approach, Sirnaomics aims to create impactful treatments for diseases with large market opportunities.
iSpace China
Series B in 2020
iSpace China, established in 2016 and headquartered in Beijing, specializes in the development of commercial launch vehicles and space shuttles for customers in the aerospace sector globally. The company focuses on providing innovative launch solutions, catering to the growing demands of the commercial space industry. With a commitment to enhancing access to space, iSpace aims to serve a diverse range of clients by offering reliable and efficient transportation options for payloads into orbit.
Beijing Yidaichu Technology
Series B in 2019
Beijing Yidaichu Technology Co., Ltd. is a company that specializes in providing software-as-a-service (SaaS) solutions for storage services tailored to small and mid-sized e-commerce operators. Founded in 2015 and headquartered in Beijing, China, the company operates an online warehouse management platform that integrates various storage resources. Its business model encompasses self-operated warehouses, contracted management, and coordination with traditional storage service providers to facilitate efficient storage solutions for its clients.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.